Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREAMLINE
2026-525933-22-00Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis and myocardial infarction (MI) comparing Aspirin + ticagrelor strategy with Aspirin + prasugrel strategy (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
ticagrelorprasugrelaspirin
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on 2026-525933-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525933-22-00.